Journal of Microbiology, Immunology and Infection, 2023 Background: Despite increasing concerns about the association between remdesivir and bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir, information on its clinical course and precipitating factors is limited. Our aim
Yan-Zuo Chen +4 more
doaj +1 more source
COVID-19 Infection: Implications for Perioperative and Critical Care Physicians. [PDF]
, 2020 Healthcare systems worldwide are responding to Coronavirus Disease 2019 (COVID-19), an emerging infectious syndrome caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with COVID-19 can progress from asymptomatic or
Greenland, John R +3 more
core
Challenges and recent progress in drug discovery for tropical diseases [PDF]
, 2018 Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi +117 more
core +2 more sources
Clinical Outcomes of Remdesivir in COVID-19 Patients with Acute Kidney Injury or Chronic Kidney Disease: A Randomized Clinical Trial [PDF]
, 2023 Background: remdesivir is an RNA polymerase inhibitor approved to treat moderate to severe Coronavirus Disease 2019 (COVID-19); however, it has not yet been authenticated to apply to patients with acute kidney injury (AKI) or chronic kidney disease (CKD).
Alirezaei, Toktam +3 more
core +2 more sources
Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [PDF]
, 2020 As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise.
Brown, Cortlyn +2 more
core
Use of remdesivir in children with covid-19 infection: A quick narrative review [PDF]
, 2021 SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in ...
Cardinale F. +10 more
core +1 more source
Asian Journal of Medical Sciences, 2021 Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers. Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate ...
Sanjana Rai +5 more
doaj +1 more source
Remdesivir and its antiviral activity against COVID-19: A systematic review
Clinical Epidemiology and Global Health, 2021 Background: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. Methods: Available publications were systematically explored on some databases and gray literature was examined.
Andri Frediansyah +4 more
doaj +1 more source
A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. [PDF]
, 2020 Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%.
Amin, Alpesh N +19 more
core +1 more source
Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 [PDF]
, 2021 Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Trasplantament de ronyó; RemdesivirCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Trasplante de riñón; RemdesivirCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Kidney transplantation; RemdesivirIntroduction ...
Arias-Cabrales, Carlos +6 more
core +1 more source